Fusidic acid for Behçet's colitis: a novel approach to T-cell specific immunosuppressive therapy

Research output: Contribution to journalJournal articleResearchpeer-review

A 33-year-old patient suffered from recurring Beh,cet's colitis despite treatment with corticosteroids and later cyclosporin. The patient was then successfully shifted from cyclosporin, a T-cell specific immunosuppressant, to fusidic acid treatment (500 mg t.i.d.). During fusidic acid treatment, he went into complete remission, and his prednisolone dose could be reduced from 30 to 5 mg/day. The case report substantiates recent in vitro data indicating that fusidic acid has a similar effect on T-cell function as cyclosporin. It is suggested that the effect of fusidic acid in other chronic immunoinflammatory diseases should be examined.

Original languageEnglish
JournalDanish Medical Bulletin (Print)
Volume38
Issue number3
Pages (from-to)284
ISSN0907-8916
Publication statusPublished - Jun 1991

    Research areas

  • Adult, Behcet Syndrome/complications, Colitis/complications, Fusidic Acid/therapeutic use, Humans, Immunosuppressive Agents/therapeutic use, Male, T-Lymphocytes/drug effects

ID: 219531521